tirzepatide approval https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound BioCentury - Nov. 8 Quick

It has been shown that the downregulation of GAP-43 precedes the onset of AD neuropathology, signifying that GAP-43 has a neuroprotective effect against the pathogenesis of AD (Perovic et al

This article gives an honest, balanced overview of tirzepatides pros and cons to help you make an informed decision

Timing your injection to align with your weekly routine, rather than fighting against it, supports the behavioral consistency that drives long-term success

While some patients may report burping as a symptom in clinical practice, formal documentation of its specific frequency is limited in the published clinical trial data